以可操作性为关键因素:用户中心设计方法推动药物安全智能系统落地
该文基于PVClinical平台的设计与实施经验,采用设计思维原则梳理药物警戒相关业务流程与用户目标,剖析阻碍智能系统被药物警戒利益相关方广泛采纳的技术、法律与医学多重障碍,指出除提供分析与统计外「可操作性」已成为整个流程识别出的运营优先事项,并强调结果需有效、可复现、可解释、可被人理解且重视可用性。
要点
- 可操作性是智能系统被药物警戒各方采纳的运营优先事项。
- 智能系统落地受技术、法律与医学多重障碍限制,需进一步阐明。
- 系统结果应有效、可复现、可解释、可被人理解并重视可用性。
核心结论
- 除提供分析与有用统计外,可操作性已成为整个设计实施流程中识别出的运营优先事项。
- 智能系统尚未被药物警戒利益相关方广泛采纳,其整合限制涉及技术、法律与医学多重障碍。
- 需强调结果有效、可复现、可解释、可被人理解,并重视可用性。
研究设计与样本
- 基于PVClinical平台(旨在支持潜在药物不良反应调查的网页平台)的设计与实施经验,以知识工程为主要技术范式。
- 依据设计思维原则,梳理平台设计过程中识别的相关业务流程与用户目标。
主要发现
- 智能系统未被制药行业、学术界/研究社区、药物安全监测组织、监管机构及医疗机构等药物警戒利益相关方广泛采纳。
- 阻碍智能系统整合的限制是多方面的,涉及技术、法律与医学障碍。
- 可操作性是贯穿整个流程识别出的运营优先事项。
临床怎么用
- 在药物警戒智能系统设计中,应将可操作性作为运营优先事项纳入考量。
- 系统输出应追求有效、可复现、可解释且可被人理解,并重视可用性。
- 需同时关注技术、法律与医学多重障碍对系统整合的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Information technology (IT) plays an important role in the healthcare landscape via the increasing digitization of medical data and the use of modern computational paradigms such as machine learning (ML) and knowledge graphs (KGs). These 'intelligent' technical paradigms provide a new digital 'toolkit' supporting drug safety and healthcare processes, including 'active pharmacovigilance'. While these technical paradigms are promising, intelligent systems (ISs) are not yet widely adopted by pharmacovigilance (PV) stakeholders, namely the pharma industry, academia/research community, drug safety monitoring organizations, regulatory authorities, and healthcare institutions. The limitations obscuring the integration of ISs into PV activities are multifaceted, involving technical, legal and medical hurdles, and thus require further elucidation. OBJECTIVE: We dissect the abovementioned limitations by describing the lessons learned during the design and implementation of the PVClinical platform, a web platform aiming to support the investigation of potential adverse drug reactions (ADRs), emphasizing the use of knowledge engineering (KE) as its main technical paradigm. RESULTS: To this end, we elaborate on the related 'business processes' (i.e. operational processes) and 'user goals' identified as part of the PVClinical platform design process based on Design Thinking principles. We also elaborate on key challenges restricting the adoption of such ISs and their integration in the clinical setting and beyond. CONCLUSIONS: We highlight the fact that beyond providing analytics and useful statistics to the end user, 'actionability' has emerged as the operational priority identified through the whole process. Furthermore, we focus on the needs for valid, reproducible, explainable and human-interpretable results, stressing the need to emphasize on usability.
引用
- Gavriilidis GI, Dimitriadis VK, Jaulent MC, et al. Identifying Actionability as a Key Factor for the Adoption of 'Intelligent' Systems for Drug Safety: Lessons Learned from a User-Centred Design Approach. Drug Saf. 2021. PMID: 34674190. doi:10.1007/s40264-021-01103-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。